Mind Cure Health Inc. (CSE: MCUR | OTCQB: MCURF | FRA: 6MH) today announced that it has signed a binding Letter of Intent with LNG Energy Group Inc. pursuant to which the Company will acquire all of the issued and outstanding securities in the capital of LNG Energy by way of a business combination transaction.

Acquisition Terms

The parties intend to enter into a definitive agreement in respect of the Transaction by December 31, 2022, or such other date as may be agreed to by LNG Energy and the Company.

It is currently anticipated that the Transaction will be effected by way of a plan of arrangement pursuant to the Business Corporations Act (British Columbia), or some other similar form of transaction, involving LNG Energy and a wholly-owned subsidiary of the Company which will constitute a reverse-takeover of the Company by LNG Energy. The resulting issuer that will exist upon completion of the Transaction (the “Resulting Issuer”) will change its business to that of LNG Energy. The Transaction is an arm’s length transaction and is expected to close in the first quarter of 2023.

If the Transaction is completed, it is anticipated that the board of directors of the Resulting Issuer shall be reconstituted to consist of such directors as LNG Energy and the Company shall determine, and certain officers of the Company shall resign and be replaced with officers appointed by the new board of directors.

Completion of the Transaction is subject to a number of conditions, including, among other items: the entering into of the Definitive Agreement; the consolidation of the Company’s existing share capital on a 2.4-for-1 basis or such other basis as mutually determined by LNG Energy and the Company (the “Consolidation”); the Company changing its name to “LNG Energy Group Inc.” or such other mutually determined name; completion of the Private Placements and Debt Financing (as described below); the acquisition by LNG of a company which holds operating oil and gas field properties in South America; receipt of all required shareholder, regulatory and third-party consents, including approval of the Transaction by the Canadian Securities Exchange (the “CSE”) and the listing of the shares of the Resulting Issuer (“Resulting Issuer Shares”) on the CSE.

Pursuant to the Transaction, all outstanding securities of LNG will be exchanged by the holders thereof for identical securities of the Resulting Issuer on a post-Consolidation one-for-one basis.

Upon entering into the Definitive Agreement in respect of the Transaction, the Company intends to issue a further press release which will disclose the finalized terms of the Transaction.

Trading of the Mind Cure Shares has been halted as a result of the announcement of the Transaction and will remain halted pending the review of the Transaction by the CSE and satisfaction of conditions of the exchange for resumption. The Company expects that trading will not resume prior to the closing of the Transaction.

Debt and Equity Financing

Pursuant to the LOI, LNG Energy will complete the following arm’s length debt and equity (on a brokered basis) financings on terms satisfactory to the Company:

      1. a brokered private placement of subscription receipts exchangeable into common shares common shares in the capital of LNG Energy (“LNG Shares“) for total proceeds of at least U.S.$15 million and no greater than U.S.$30 million (the “Subscription Receipt Private Placement“); and
      2. a bank debt financing of between U.S.$65 million and U.S.$85 million (the “Debt Financing“).

In addition, the Company, either directly or indirectly through a wholly-owned subsidiary of the Company, or through a combination thereof, will complete a non-brokered private placement of units (“Units“) at a price of $0.05 per Unit comprised of one (1) common share in the capital of the Company (“Mind Cure Shares“) and up to one (1) Mind Cure Share purchase warrant with an exercise price of at least $0.07 per warrant for total proceeds of up to $4 million (the “Unit Private Placement” and, together with the Subscription Receipt Private Placement, the “Private Placements“), provided that the issue and exercise price of the securities comprising the Unit Private Placement may be such lower amount as agreed by the parties and acceptable to the CSE. 

The use of proceeds from the Private Placements and the Debt Financing shall be to fund working capital and to acquire certain natural gas assets located in Latin America.

Further Information

The final structure of the Transaction and the Unit Private Placement will be determined by the parties following receipt of tax, corporate and securities law advice.

There can be no assurance that the Transaction, the Debt Financing or the Private Placements will be completed as proposed, or at all. Investors are cautioned that, except as disclosed in the Listing Statement to be prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of the Company should be considered highly speculative.

None of the securities to be issued in connection with the Transaction, the Private Placements or the Debt Financing have been, or will be, registered under the United States Securities Act of 1933, as amended (the “1933 Act“), or any state securities laws, and may not be offered or sold within the United States or to any U.S. Person (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws or an exemption from such registration is available. This press release does not constitute an offer to sell or a solicitation of an offer to sell any securities in any jurisdiction where such offer or solicitation would be unlawful, including the United States.

About LNG Energy Group Inc.

LNG Energy is a private company focused on the acquisition of natural gas production and exploration assets in Latin America.  For more information, please visit www.lngenergygroup.com.

About Mind Cure Health Inc.

Mind Cure was historically a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health.